Samalizumab
- Generic Name
- Samalizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1073059-33-2
- Unique Ingredient Identifier
- 64EUX713G6
- Background
Samalizumab has been used in trials studying the treatment of Multiple Myeloma and B-cell Chronic Lymphocytic Leukemia.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Samalizumab in Patients With Advanced Cancer
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02987504
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00648739
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath